Bottom line
LHCAX vs QAAGZX: the short answer
LHCAX (Lord Abbett Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) are both mutual funds.
But QAAGZX is far broader, holding 277 positions to 61 for LHCAX, so beyond the top names it adds exposure LHCAX doesn't have.
QAAGZX is cheaper at 0.86% vs 1.03% — a difference of $17 a year per $10,000 invested.
Over five years, QAAGZX returned +4.1% a year vs +3.1% for LHCAX.
LHCAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
LHCAX vs QAAGZX side by side
| LHCAX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Lord Abbett | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.03% | 0.86% |
| Annual cost per $10k | $103 | $86 |
| 10-yr cost on $10k (prospectus) | $3,961 | $1,061 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +10.9% | +18.1% |
| 5-yr return (annualized) | +3.1% | +4.1% |
| 10-yr return (annualized) | — | +9.0% |
| Best quarter | +21.5% | +23.4% |
| Worst quarter | −11.4% | −15.8% |
| Net assets (fund) | $8.6M | $751.7M |
| Number of holdings | 61 | 277 |
| Portfolio turnover | 91% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LHCAX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +18.1% | −0.4% |
| 2024 | +7.3% | +1.7% | +5.6% |
| 2023 | +2.9% | +3.0% | −0.0% |
| 2022 | −12.0% | −12.5% | +0.4% |
| 2021 | +8.2% | +13.1% | −4.9% |
| 2020 | +37.1% | +29.6% | +7.5% |
Source: Fund prospectus bar charts
Holdings overlap
10 of LHCAX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | LHCAX | QAAGZX |
|---|---|---|
| Eli Lilly & Co | 10.40% | 14.06% |
| UnitedHealth Group Inc | 5.39% | 5.88% |
| Johnson & Johnson | 4.96% | 6.64% |
| Natera Inc | 3.60% | 1.44% |
| Gilead Sciences Inc | 3.53% | 2.79% |
| CVS Health Corp | 3.33% | 0.93% |
| Guardant Health Inc | 2.61% | 1.22% |
| Thermo Fisher Scientific Inc | 2.31% | 2.53% |
| Vertex Pharmaceuticals Inc | 2.24% | 2.26% |
| Protagonist Therapeutics Inc | 1.44% | 0.85% |
Source: SEC Form N-PORT
LHCAX top 10
- Eli Lilly & Co — 10.40%
- UnitedHealth Group Inc — 5.39%
- Johnson & Johnson — 4.96%
- Novartis AG — 4.19%
- Natera Inc — 3.60%
- Gilead Sciences Inc — 3.53%
- CVS Health Corp — 3.33%
- Guardant Health Inc — 2.61%
- Galderma Group AG — 2.60%
- Thermo Fisher Scientific Inc — 2.31%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between LHCAX and QAAGZX?
Which is cheaper, LHCAX or QAAGZX?
Should I own both LHCAX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.